Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Income towards Parent Company: 2018-2021

Historic Income towards Parent Company for Black Diamond Therapeutics (BDTX) over the last 4 years, with Dec 2021 value amounting to -$123.4 million.

  • Black Diamond Therapeutics' Income towards Parent Company fell 16.25% to -$25.5 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$111.6 million, marking a year-over-year decrease of 68.00%. This contributed to the annual value of -$123.4 million for FY2021, which is 88.32% down from last year.
  • Latest data reveals that Black Diamond Therapeutics reported Income towards Parent Company of -$123.4 million as of FY2021, which was down 88.32% from -$65.5 million recorded in FY2020.
  • In the past 5 years, Black Diamond Therapeutics' Income towards Parent Company ranged from a high of -$8.9 million in FY2018 and a low of -$123.4 million during FY2021.
  • Over the past 3 years, Black Diamond Therapeutics' median Income towards Parent Company value was -$65.5 million (recorded in 2020), while the average stood at -$72.6 million.
  • Data for Black Diamond Therapeutics' Income towards Parent Company shows a maximum YoY slumped of 224.39% (in 2019) over the last 5 years.
  • Over the past 4 years, Black Diamond Therapeutics' Income towards Parent Company (Yearly) stood at -$8.9 million in 2018, then plummeted by 224.39% to -$28.9 million in 2019, then crashed by 126.98% to -$65.5 million in 2020, then plummeted by 88.32% to -$123.4 million in 2021.